Fool - Investing News
02 Jun 2026, 03:15 UTC · 2h ago
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
Search tags
Fool - Investing News
02 Jun 2026, 03:15 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
Bristol Myers Squibb faces upcoming patent expirations for cancer drugs Revlimid and Pomalyst in 2026, and Eliquis in 2028. — Patent cliffs typically lead to significant revenue loss due to generic competition, creating material pressure on top and bottom lines.
-0.60Bristol Myers Squibb's price-to-earnings ratio is approximately 16x, which is significantly lower than the S&P 500's 27x and the industry's 24x. — A low P/E relative to peers and the broader market suggests the stock is undervalued, attracting value investors.
+0.30The company offers a dividend yield of 4.4%, substantially higher than the S&P 500 index (1.1%) and the drug maker average (1.7%). — High yields provide immediate income appeal and a floor for the stock price, though offset by a high 70% payout ratio.
+0.20Ticker attribution
Continue reading
6 related stories
Model heads
The company has an attractive valuation and dividend yield, though it faces near-term headwinds from patent expirations.
Mentioned as a competitor that will face generic competition for the drug Eliquis in 2028.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 10 offered
24/7 Wall Street
8h ago
